IMDX
Insight Molecular Diagnostics Inc.
Biotechnology
Market Cap$87M
5Y Perf.-91.0%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
IMDX vs NTRA
Revenue, margins, valuation, and 5-year total return — side by side.
NTRA
Natera, Inc.
Medical - Diagnostics & Research
Market Cap$31.16B
5Y Perf.+401.3%
IMDX vs NTRA — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | IMDX | NTRA |
|---|---|---|
| Industry | Biotechnology | Medical - Diagnostics & Research |
| Market Cap | $87M | $31.16B |
| Revenue (TTM) | $4M | $2.31B |
| Net Income (TTM) | $-61M | $-208M |
| Gross Margin | 54.7% | 64.8% |
| Operating Margin | -13.9% | -13.4% |
| Total Debt | $4M | $214M |
| Cash & Equiv. | $9M | $1.08B |
IMDX vs NTRA — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
IMDX
NTRA
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Insight Molecular D… (IMDX) | 100 | 9.0 | -91.0% |
| Natera, Inc. (NTRA) | 100 | 501.3 | +401.3% |
Price return only. Dividends and distributions are not included.
Quick Verdict: IMDX vs NTRA
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: NTRA leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Insight Molecular Diagnostics Inc. is the stronger pick specifically for capital preservation and lower volatility and recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
IMDX
Insight Molecular Diagnostics Inc.
The Income Pick
IMDX is the clearest fit if your priority is income & stability and sleep-well-at-night.
- Dividend streak 1 yrs, beta 1.18
- Lower volatility, beta 1.18, current ratio 1.62x
- Beta 1.18, current ratio 1.62x
Best for: income & stability and sleep-well-at-night
NTRA
Natera, Inc.
The Growth Play
NTRA carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth 35.9%, EPS growth 0.7%, 3Y rev CAGR 41.1%
- 20.9% 10Y total return vs IMDX's -94.6%
- 35.9% revenue growth vs IMDX's 25.1%
Best for: growth exposure and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | NTRA | 35.9% revenue growth vs IMDX's 25.1% |
| Quality / Margins | NTRA | -9.0% margin vs IMDX's -13.8% |
| Stability / Safety | IMDX | Beta 1.18 vs NTRA's 1.26 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | IMDX | +75.3% vs NTRA's +37.3% |
| Efficiency (ROA) | NTRA | -10.6% ROA vs IMDX's -138.3% |
IMDX vs NTRA — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2024
FY 2025
IMDX vs NTRA — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLNTRALAGGINGIMDX
IMDXInsight Molecular Dia…
0leads
NTRANatera, Inc.
4leads
6 Total Categories
CATEGORYLEADERvs IMDXMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
NTRA5/6
Valuation MetricsMultiples, price ratios, and targets
NTRA2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
NTRA6/7
Total Returns1Y, 3Y, 5Y total returns with dividends
NTRA5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
NTRA leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
NTRA is the larger business by revenue, generating $2.3B annually — 523.9x IMDX's $4M. Profitability is closely matched — net margins range from -9.0% (NTRA) to -13.8% (IMDX). On growth, IMDX holds the edge at +126.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | IMDXInsight Molecular… | NTRANatera, Inc. |
|---|---|---|
| RevenueTrailing 12 months | $4M | $2.3B |
| EBITDAEarnings before interest/tax | -$59M | -$310M |
| Net IncomeAfter-tax profit | -$61M | -$208M |
| Free Cash FlowCash after capex | -$24M | $97M |
| Gross MarginGross profit ÷ Revenue | +54.7% | +64.8% |
| Operating MarginEBIT ÷ Revenue | -13.9% | -13.4% |
| Net MarginNet income ÷ Revenue | -13.8% | -9.0% |
| FCF MarginFCF ÷ Revenue | -5.4% | +4.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | +126.1% | +39.8% |
| EPS Growth (YoY)Latest quarter vs prior year | +65.4% | +185.4% |
NTRA leads this category, winning 5 of 6 comparable metrics.
Valuation Metrics
NTRA leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | IMDXInsight Molecular… | NTRANatera, Inc. |
|---|---|---|
| Market CapShares × price | $87M | $31.2B |
| Enterprise ValueMkt cap + debt − cash | $82M | $30.3B |
| Trailing P/EPrice ÷ TTM EPS | -1.06x | -144.62x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 46.02x | 13.51x |
| Price / BookPrice ÷ Book value/share | — | 17.55x |
| Price / FCFMarket cap ÷ FCF | — | 285.53x |
NTRA leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
NTRA leads this category, winning 6 of 7 comparable metrics.
Profitability & Efficiency
NTRA delivers a -15.3% return on equity — every $100 of shareholder capital generates $-15 in annual profit, vs $-15 for IMDX. On the Piotroski fundamental quality scale (0–9), NTRA scores 5/9 vs IMDX's 4/9, reflecting solid financial health.
| Metric | IMDXInsight Molecular… | NTRANatera, Inc. |
|---|---|---|
| ROE (TTM)Return on equity | -14.8% | -15.3% |
| ROA (TTM)Return on assets | -138.3% | -10.6% |
| ROICReturn on invested capital | — | -36.1% |
| ROCEReturn on capital employed | -127.8% | -18.3% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 5 |
| Debt / EquityFinancial leverage | — | 0.13x |
| Net DebtTotal debt minus cash | -$5M | -$862M |
| Cash & Equiv.Liquid assets | $9M | $1.1B |
| Total DebtShort + long-term debt | $4M | $214M |
| Interest CoverageEBIT ÷ Interest expense | -536.86x | -25.21x |
NTRA leads this category, winning 6 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
NTRA leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in NTRA five years ago would be worth $21,587 today (with dividends reinvested), compared to $579 for IMDX. Over the past 12 months, IMDX leads with a +75.3% total return vs NTRA's +37.3%. The 3-year compound annual growth rate (CAGR) favors NTRA at 60.6% vs IMDX's -2.6% — a key indicator of consistent wealth creation.
| Metric | IMDXInsight Molecular… | NTRANatera, Inc. |
|---|---|---|
| YTD ReturnYear-to-date | -30.7% | -3.9% |
| 1-Year ReturnPast 12 months | +75.3% | +37.3% |
| 3-Year ReturnCumulative with dividends | -7.5% | +314.0% |
| 5-Year ReturnCumulative with dividends | -94.2% | +115.9% |
| 10-Year ReturnCumulative with dividends | -94.6% | +2089.4% |
| CAGR (3Y)Annualised 3-year return | -2.6% | +60.6% |
NTRA leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — IMDX and NTRA each lead in 1 of 2 comparable metrics.
Risk & Volatility
IMDX is the less volatile stock with a 1.18 beta — it tends to amplify market swings less than NTRA's 1.26 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NTRA currently trades 85.7% from its 52-week high vs IMDX's 58.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | IMDXInsight Molecular… | NTRANatera, Inc. |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.18x | 1.26x |
| 52-Week HighHighest price in past year | $8.51 | $256.36 |
| 52-Week LowLowest price in past year | $2.33 | $131.81 |
| % of 52W HighCurrent price vs 52-week peak | +58.3% | +85.7% |
| RSI (14)Momentum oscillator 0–100 | 60.5 | 57.1 |
| Avg Volume (50D)Average daily shares traded | 323K | 1.3M |
Evenly matched — IMDX and NTRA each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates IMDX as "Buy" and NTRA as "Buy". Consensus price targets imply 111.7% upside for IMDX (target: $11) vs 19.4% for NTRA (target: $263).
| Metric | IMDXInsight Molecular… | NTRANatera, Inc. |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $10.50 | $262.50 |
| # AnalystsCovering analysts | 11 | 27 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 1 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
NTRA leads in 4 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics. 1 category is tied.
Best OverallNatera, Inc. (NTRA)Leads 4 of 6 categories
Loading custom metrics...
IMDX vs NTRA: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is IMDX or NTRA a better buy right now?
For growth investors, Natera, Inc.
(NTRA) is the stronger pick with 35. 9% revenue growth year-over-year, versus 25. 1% for Insight Molecular Diagnostics Inc. (IMDX). Analysts rate Insight Molecular Diagnostics Inc. (IMDX) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — IMDX or NTRA?
Over the past 5 years, Natera, Inc.
(NTRA) delivered a total return of +115. 9%, compared to -94. 2% for Insight Molecular Diagnostics Inc. (IMDX). Over 10 years, the gap is even starker: NTRA returned +20. 9% versus IMDX's -94. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — IMDX or NTRA?
By beta (market sensitivity over 5 years), Insight Molecular Diagnostics Inc.
(IMDX) is the lower-risk stock at 1. 18β versus Natera, Inc. 's 1. 26β — meaning NTRA is approximately 7% more volatile than IMDX relative to the S&P 500.
04Which is growing faster — IMDX or NTRA?
By revenue growth (latest reported year), Natera, Inc.
(NTRA) is pulling ahead at 35. 9% versus 25. 1% for Insight Molecular Diagnostics Inc. (IMDX). On earnings-per-share growth, the picture is similar: Natera, Inc. grew EPS 0. 7% year-over-year, compared to -24. 3% for Insight Molecular Diagnostics Inc.. Over a 3-year CAGR, NTRA leads at 41. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — IMDX or NTRA?
Natera, Inc.
(NTRA) is the more profitable company, earning -9. 0% net margin versus -32. 3% for Insight Molecular Diagnostics Inc. — meaning it keeps -9. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NTRA leads at -13. 4% versus -32. 5% for IMDX. At the gross margin level — before operating expenses — NTRA leads at 64. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — IMDX or NTRA?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is IMDX or NTRA better for a retirement portfolio?
For long-horizon retirement investors, Natera, Inc.
(NTRA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 26)). Both have compounded well over 10 years (NTRA: +20. 9%, IMDX: -94. 6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between IMDX and NTRA?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(IMDX: 126.1% · NTRA: 39.8%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.